NCT05989204 is a Phase 1 clinical trial of TmCD19-IL18 in Non Hodgkin Lymphoma, sponsored by University of Pennsylvania.

Who is sponsoring NCT05989204?

NCT05989204 is sponsored by University of Pennsylvania.

What drugs are being tested in NCT05989204?

Interventions in NCT05989204: TmCD19-IL18.

What condition does NCT05989204 study?

NCT05989204 studies Non Hodgkin Lymphoma.

Is NCT05989204 still recruiting?

NCT05989204 is currently recruiting now. Last updated 5 September 2025.

Last reviewed 2025-09-05 · How we verify

NCT05989204

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TmCD19-IL18 in CD19+ Cancers

Recruiting now Phase 1 Last updated 5 September 2025

What this trial tests

Phase 1 trial testing TmCD19-IL18 in Non Hodgkin Lymphoma in 24 participants. Currently enrolling.

Timeline

13 November 2023

Primary endpoint
1 October 2026

1 October 2041

Quick facts

Lead sponsor	University of Pennsylvania
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	13 November 2023
Primary completion	1 October 2026
Estimated completion	1 October 2041
Sites	1 location across United States

Drugs / interventions tested

TmCD19-IL18 — full drug profile →

Conditions studied

Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →

Sponsor

University of Pennsylvania

Who can join

18 and older, any sex, with Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I, open-label dose finding study to assess the safety and feasibility, pharmacokinetics, and preliminary efficacy of TmCD19-IL18 CAR T cells in patients with CD19+ cancers. This study will take place in two parts: a Dose-Finding Phase to determine the maximum tolerate dose (MTD), followed by a Dose Expansion Phase. In the Dose-Finding Phase, dose levels will be evaluated using a 3+3 dose escalation design to determine the MTD. Cumulative safety experience and manufacturing feasibility data from the Dose-Finding Phase will then be used to identify the dose level that can be progressed into the Dose Expansion Phase.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T cells in solid tumors: Challenges and breakthroughs.
Escobar G, Berger TR, Maus MV. · · 2025 · cited 17× · PMID 40945517 · DOI 10.1016/j.xcrm.2025.102353
IL-18 and IL-18BP: A Unique Dyad in Health and Disease.
Novick D. · · 2024 · cited 17× · PMID 39769266 · DOI 10.3390/ijms252413505
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target.
Shukla D, Gabunia K, McGettigan SE, Patel PR, et al · · 2025 · cited 3× · PMID 40298385 · DOI 10.1158/2326-6066.cir-24-1347
How can we balance risk and benefit of interleukin-18 armored T cell therapies?
Vicenova P, Maher J. · · 2026 · PMID 41728085 · DOI 10.3389/ebm.2026.10938
Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity.
Zhang X, Aimaiti G, Guan Y, Sha Y, et al · · 2026 · PMID 41631887 · DOI 10.1002/advs.202518547

Verify or expand the search:

Other recruiting trials for Non Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting

Other University of Pennsylvania trials

Trials by the same sponsor.

NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05989204 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
Last refreshed: 5 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05989204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing